News

In a retrospective interventional cohort study, the investigators analyzed the outcomes of 80 patients with submacular hemorrhages who were treated with subretinal aflibercept or intravitreal aflibercept.

At the 2024 ARVO meeting, Andrew D. Pucker, OD, PhD, presented a paper on measuring meibomian gland morphology

Allen Ho, MD, presented on the 12-month results of an mutation agnostic optogenetic programme at the ARVO 2024 meeting

SriniVas R Sadda, MD, presented "Post Hoc Analysis of a Phase 3 Trial on SB15 (Proposed Aflibercept Biosimilar): Assessment on Pre-to-Post Switching Efficacy and Safety in Neovascular Age-related Macular Degeneration."

A singular celebration of science over the decades

At this year's ARVO meeting, Allen Ho, MD, presented a paper on presenting a paper on the 12 month results of a mutation agnostic optogenetic program for patients with severe vision loss from retinitis pigmentosa.

Three leaders in glaucoma research, retina care and refractive surgery share their expertise

Astigmatic values differed between K and TK readings

Several presentations at Retina World Congress 2024 highlight the importance of diversity equity and inclusion in the retina field.

At this year's ARVO meeting, the Eye Care Network got a glimpse at the future of paediatric myopia control research

Several companies working in the retina space have shared that they plan to release data at this year’s meeting in Fort Lauderdale, Florida.

Considering ages and stages of myopia progression in a therapeutic timeline

Incoming ARVO president SriniVas R. Sadda, MD, discussed major challenges in vision science research and how annual meetings inspire innovation in ophthalmology

At this year's ARVO meeting, SriniVas R Sadda, MD, presented "Post Hoc Analysis of a Phase 3 Trial on SB15 (Proposed Aflibercept Biosimilar): Assessment on Pre-to-Post Switching Efficacy and Safety in Neovascular Age-related Macular Degeneration."

An analysis showed an association between patients who previously had undergone intravitreal injections and cataract surgery and a higher risk of the development of a non-clearing vitreous hemorrhage, retinal detachment, retinal tear, and glaucoma surgery.

Pucker shares topline results from a study that investigated the difference in meibomobian gland morphology when measured with a Visante OCT versus an OCULUS Keratograph 5M

Voretigene neparvovec (Luxturna, Spark Therapeutics, Inc.) was shown to be safe and effective in real-world settings.

Huntington's disease (HD) is an autosomal-dominant, fully-penetrant, neurodegenerative disease that most commonly affects adults during middle age.

The mutant huntingtin protein in tear fluid may have the potential to serve as an early marker of changes in Huntington disease

In a conversation with the Eye Care Network at ARVO, Osamah Saeedi, MD, MS, Associate Professor of Ophthalmology, Director of Clinical Research and Director of the Glaucoma Division at the University of Maryland School of Medicine, explained the key findings from his poster.

Tylectomy indicates surgical resection of retinoblastomas via pars plana vitrectomy with intraoperative chemotherapy infusion.

Tylectomy indicates surgical resection of retinoblastomas via pars plana vitrectomy with intraoperative chemotherapy infusion.

Dustin Morley, PhD, principal research scientist at LENSAR, discusses research on applying deep learning to benefit FLACS procedures.

Sadda discusses his goals for ARVO, focusing on enhancing the organization's role in promoting scientific exchange in vision research. He underscores the significance of the annual meetings for networking and driving innovation in ophthalmology.

In a conversation with the Eye Care Network at ARVO, Corradetti, a research scientist at Doheny Eye Institute, explained the key findings from her work.

Four poster presentations at the Association for Research in Vision and Ophthalmology’s (ARVO) 2024 Annual Meeting in Seattle, Washington, demonstrate the possibilities.